Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers
ApTOLL, a new modulator of Toll-like receptor 4, has demonstrated safety and efficacy in healthy subjects and in stroke patients; however, the route of administration used so far (30 min infusion) can potentially be an issue in the acute stroke units where “time is brain.” To safely reduce the time...
Saved in:
Main Authors: | Macarena Hernández-Jiménez, Samuel Martín-Vílchez, Gina Mejía-Abril, Manuel Roman, Sergio Luquero-Bueno, David Piñeiro, Marc Ribó, Francisco Abad-Santos, Dolores Ochoa |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253124003226 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nucleic acid therapeutics: Past, present, and future
by: Sajid Naeem, et al.
Published: (2025-03-01) -
DeepAptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model
by: Xin Yang, et al.
Published: (2025-03-01) -
In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01) -
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01) -
Unveiling sequence-agnostic mixed-chemical modification patterns for splice-switching oligonucleotides using the NATURA platform
by: Tommaso Tabaglio, et al.
Published: (2025-03-01)